Streams straight from the publisher. PodNod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Meet Ron Cooper And enGene
- 3:35Lessons From Global Scale At BMS
- 7:45Becoming The “Fix-It” Operator
- 12:20Why Leave Big Pharma For Biotech
- 15:24Albireo’s Science And Patient Need
- 19:43Syncing Science, People, And Capital
- 24:36Fundraising Creativity And Storycraft
- 29:20IPO Detour And Near-Death Moments
- 34:10How To Get Bought Without Selling
- 39:15Build Optionality Into Commercial Plans
- 44:00The Hard Transitions: R&D To Commercial
- 49:10Pediatric Vouchers And Policy Gaps
- 50:20Why enGene And Nonviral Gene Therapy
- 54:30The Community Urologist Reality And Market Outlook